Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Pertuzumab (Primary) ; Gemcitabine; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 30 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 10 Jun 2017 Biomarkers information updated